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Arsenic is a contaminant of drinking water in many parts of the world.  A number 
of epidemiological studies have correlated arsenic exposure with cancer, skin diseases, 
cardiovascular diseases, and adverse developmental outcomes such as stillbirths, 
spontaneous abortions, neonatal mortality, low birth weight, and delays in the use of 
musculature. The current study used C2C12 mouse myoblast cells to examine whether 
low concentrations of arsenic could alter their differentiation into myotubes, which would 
indicate that arsenic has the ability to act as a developmental toxicant.  Myoblast cells 
were exposed to 20nM sodium arsenite and allowed to differentiate into myotubes and 
expression of the muscle-specific transcription factor myogenin, along with the 
expression of myosin light chain 2, and tropomyosin were investigated using real time 
PCR and immunofluorescence.  Exposing C2C12 cells to 20nM sodium arsenite delayed 
the differentiation process, as evidenced by a significant reduction in the number of 
multinucleated myotubes.  Additionally, arsenic exposure caused a time-dependant 
decrease in myogenin mRNA expression, as compared to the control cells, starting on 
day two of the differentiation process.  Arsenic reduced myogenin mRNA levels by 1.4-
fold on day two, 2.7-fold on day three, and 5.1-fold on day four of differentiation.  This 
reduction in transcript number was confirmed by immunofluorescence, which also 
showed a decrease in the total number of nuclei expressing myogenin protein.  
Interestingly, myosin light chain 2 mRNA was significantly unregulated in the arsenic-





demonstrated that low concentrations of arsenic are able to disturb the differentiation 
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Arsenic is a ubiquitous element that can come in many oxidative states:  -3, 0, +3 and +5.  
It ranks 12th in the body, 14th in seawater and 20th in the earth’s crust and can be found in 
an inorganic or organic form (Mandal B.D., 2002). The trivalent inorganic form being the 
one humans are exposed to the most. This exposure can be from natural sources like soil, 
water, or food sources and from human sources like industrial pollution, mining (copper 
smelting) and medication.   
Distribution  
Today, a number of countries are affected by arsenic and its detrimental effects but 
Bangladesh and West Bengal have the largest affected areas. In these countries, the 
surface water is contaminated with pathogens, so tube wells were dug to reach the 
groundwater to use for drinking (Karn and Harada, 2001).  Unfortunately, the well water 
contains high amounts of inorganic arsenic (Chowdhury et al., 2000). When arsenic is 
found in high concentrations in the bedrock it is usually paired with sulfide minerals. The 
most common mineral forms are arsenian pyrite (Fe(S,As)2) and arseno pyrite (FeAsS), 
and it can also come in the forms of realgar (AsS), orpiment (As2S3), or scorodite 
(FeAsO42H2O).  Large concentrations of arsenic in drinking water usually come from 
aquifers that are located in alluvial and delta planes. They create the best circumstances 
for the arsenic to separate from its mineral form through redox reactions that normally 
occur between a pH of 6.5-8.5.  Hydrologically closed basin regions and a high pH of 





poor adsorption of arsenic into evaporite minerals will only occur at a high salinity (> 9 
molar) and as long as the redox stability of As(V) are at moderately reducing conditions 
and high pH values occur, it will decrease As affinity to the mineral surfaces  (Levy, 
1999). In southeastern Bangladesh alone, 90% of the boreholes have an arsenic 
concentration greater than 50µg/L, which is due to the area being part of a large delta 
plane (Figure 1).The World Health Organization (WHO) has changed its limits of arsenic 
in the groundwater throughout the decades with the increasing concern for its adverse 
effects on human health.     
 
 








In 1958, the regulation was 200 ppb, this amount was lowered to 50 ppb in 1963, 
and finally in 1993 was  lowered to 10 ppb (WHO, 2003).  The U.S. itself made the 
standard of 10 ppb effective on February 22, 2002, with water systems needing to be in 
compliance with the new standard by January 23, 2006.  In the U.S., 31,350 public and 
private water supplies were tested for arsenic concentration from 1973 to 2001. A map 
that was developed from this data shows the different arsenic concentrations across the 
states (Figure 2).   In certain areas like California (highest concentration was 2600ppb), 
and Nevada (highest concentration was 2200 ppb) (Ryker, 2001), the high concentrations 
are largely due to evaporation and concentration in shallow ground water.  
 








Arsenic trioxide has been used as treatment for different types of leukemia, like 
multidrug-resistant human myeloid leukemia, acute promyelocytic leukemia, acute 
lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkin’s lymphoma, 
Hodgkin’s disease, chronic lymphocytic leukemia, myelodysplastic syndrome, and 
multiple myeloma (Shen et al., 1997; Li and Broome, 1999; Perkins et al., 2000; Murgo, 
2001; Chen et al., 2002).  The function of arsenic is to induce cell cycle arrest and 
apoptosis in the leukemia cells, but the same outcomes may also happen in noncancerous 
cells (Qian et al., 2007).  
In a study done by Perkins et. al, human promyelocytic leukemic cells (HL-60) 
and myelogenous leukemia cells (K562) that were incubated in arsenic trioxide saw a 
reduction in growth with a LC50 between 0.8 and 1.5 µmol/L. At 2 µmol/L of arsenic 
trioxide, after 7 days of incubation, 30 to 50% of cells, in all cell lines, showed 
morphologic features of apoptosis, like blebbing and an expression of the cell-surface 
phosolipid phosphatidylserine, that is only released from the cell’s cytosol to the cells 
surface during apoptosis (Perkins et al., 2000). Another study showed that arsenic 
trioxide disrupted tubulin polymerization in K562 cells at concentrations ranging from 






When inorganic arsenic enters the body, the proposed metabolic pathway starts 
with the liver where it is metabolized through an oxidative process in which the trivalent 
inorganic arsenic will gain a methyl group that is donated from S-adenosylmethionine 
(SAM) (Fig. 3) (Aposhian, 1997).  This process changes the oxidative state to a 
pentavalent form, creating methylarsenoic acid (MAsV). From there, two electrons are 
removed from arsenic through a thiol oxidation process to reduce As(V) to As(III). 
Another oxidative methylation can take place creating dimethylarsinic acid (DMAsV) 
(Thomas et al., 2004).    Normally the methylation and reduction process would be 
considered a detoxification step, with the arsenic metabolites exiting through the urine, 
but some studies have shown that the methylated species might also contribute to the 
effects seen with arsenic exposure (Kaise et al., 1989, Styblo, 2000 #2750, Vega, 2001 
#2748).  
 Figure. 3 Proposed methylation process with the methyl donor  SAM 





An in vivo study examined the effects that methylarsonic acid, CH3AsO(OH)2 
(MAA), dimethylarsininc acid, (CH3)2AsO(OH) (DMAA), and trimethylarsine oxide had 
when orally administered to mice (Kaise et al., 1989).   DMAA had the highest toxicity 
of the methylated species with a LD50 of 1.2 g/kg, while MAA and TMAO had LD50 of 
1.8 and 10.6 g/kg respectively.  These concentrations are below arsenic trioxide’s acute 
toxicity in which two mouse studies had an oral LD50 of 26-48 mg/kg (Kaise et al., 1985) 
(Harrison et al., 1958). Even though methylated species are not lethal it is important to 
consider their biological effects. The toxicity of inorganic arsenic, trivalent and 
pentavalent methylated arsenicals, was investigated in cultured human hepatocytes, 
bronchial cells, keratinocytes and urothelium cells, along with rat hepatocytes (Styblo et 
al., 2000).  Trivalent monomethylated arsenic was found to be less cytotoxic when 
compared to inorganic arsenic(III) in all cell types (Styblo et al., 2000) The cell line with 
the greatest methylation capacity were the rat hepatocytes followed by the human 
hepatocytes, keratinocytes and brionchial cells. Another study also investigated the 
effects of exposed human epidermal keratinocytes to the different oxidative states of 
arsenic (Vega et al., 2001). They observed that the lower the oxidative state, the more 
cytotoxic the arsenic was and within the pentavalent oxidative states the methylated 
versions had the higher cytotoxicity:  iAsIII (arsenite) > MAsIIIO (methylarsine oxide) > 
DMAsIIIGS (dimethylarsinous acid with glutathione) > DMAsV (dimethylarsinic acid) > 
MAsV (methylarsonic acid) > iAsV(arsenate) (Vega et al., 2001). This shows that the 
methylated species of arsenic may contribute to the adverse effects connected with 






Chronic arsenic exposure has multiple aliments connected to it but there is no 
specific order in which they appear, so diagnosis of arsenic exposure can be difficult. 
External characteristics can consist of dermal changes like lesions, pigmentation changes, 
increase of keratoses, or skin cancers (Tondel M., 1999; Mandal B.D., 2002). The 
internal ailments associated with exposure range from cardiovascular diseases, different 
forms of cancer, respiratory or gastrointestinal problems to developmental problems 
(Soffritti et al., 2006) (Shi et al., 2004). A clear mechanism or pathway for these ailments 
is still unknown but there have been various hypotheses like alteration of the DNA 
methylation pattern, impairment of DNA repair mechanisms, genetic damage or 
programmed cell death (Hughes, 2002).  
For example, it is known that arsenic can modify DNA methylation patterns 
(Reichard et al., 2007). Gene transcription can be regulated through methylation and an 
alteration to DNA methylation patterns can cause genes to be over- or under-expressed 
(Newell-Price et al., 2000). A study showed that when the A549 human adenocarcinoma 
cell line was exposed to various concentrations of sodium arsenite, sodium arsenate, and 
DMAsV, both sodium arsenite (0.08-2 µM) and sodium arsenate (30-300 µM) 
hypermethylated the promoter region of the tumor suppressor gene, p53(Mass and Wang, 
1997), which indicates that increasing arsenic concentrations likely suppressed p53 





Arsenic exposure can both increase genetic damage as well as alter DNA repair 
mechanisms (Andrew et al., 2006).  There are three levels of genetic damage that can 
occur. The most basic is point mutation and frame shift mutation; the next level is 
chromosome or chromatid breaks and aneuploidy, otherwise known as a gain or loss of a 
whole chromosome. The final level of genetic damage is spindle disruption at metaphase 
and anaphase during the cell cycle and dicentric chromosome formation, where a 
chromosome contains two centromeres instead of one (Gonzalgo and Jones, 1997). A 
common test for mutation is the mouse lymphoma assay which looks at thymidine kinase 
(TK), an enzyme that takes part in the recycling of free thymidine which can get 
incorporated into DNA. A toxic analogue to thymidine is trifluorothymidine (TFT) and if 
thymidine kinase is active the TFT can disrupting DNA metabolism and cause cell death. 
The mouse lymphoma assay uses a cell line that only has one functioning TK gene and if 
the toxicant in question is mutagen the cells will be unaffected with addition of TFT, due 
to the loss of the TK gene. When mouse lymphoma cells were exposed to sodium 
arsenite, arsenic trioxide, monomethylarsonic acid and dimethylarsinic acid at 10µM , all 
were found to cause mutations at the TK gene (Soriano et al., 2007).  
The nucleotide excision repair pathway, which fixes nucleotide deletions caused 
by UV radiation, was studied to see if arsenic impaired it in a human lymphoblastoid cell 
line (TK6) (Danaee et al., 2004). When 1 and 5 µM sodium arsenite were combined with 
UV radiation, there was a synergistic effect on the number of mutations in the TK gene 
(Danaee et al., 2004). To determine if the UV repair pathway was affected by arsenic, a 





observed that the repair pathway was operational when the cells were exposed to just UV 
because of the low amount of comet scores.  However, when the cells were exposed to 
both UV and arsenic, the comet scores were higher, implying that DNA repair 
mechanisms were impaired (Danaee et al., 2004).  
Finally, programmed cell death follows highly regulated pathways and can lead to 
either apoptotic or autophagic cell death (Burchell et al., 1991).  In apoptosis, the 
activation of various caspases lead to the formation of blebs, bulges that separate from 
the cell, taking a portion of cytoplasm with them containing the organelles of the cell so 
that other neighboring cells will not be affected.  Autophagic cell death differs in that it 
forms vacuoles in which organelles of the cell are destroyed while maintaining membrane 
formation (Cuervo, 2004).  A variety of studies have shown that arsenic is able to induce 
programmed cell death (Soignet et al., 1998; Li and Broome, 1999; Kong et al., 2005; 
Bashir et al., 2006; Binet et al., 2006; Cheung et al., 2006; Qian et al., 2007; Banerjee et 
al., 2008; Leu and Mohassel, 2009).  For example, when K529 myeloid leukemia cells 
were exposed to 2.5µM arsenic trioxide, only 36 ±5 % of the cells survived and those that 
did showed high levels of the apoptotic marker annexin V 12 hours post-exposure (Li and 
Broome, 1999).  Using 4µM arsenic trioxide, another study not only reported apoptosis in 
two leukemia cell lines (Molt-4 and Mutz-1) but saw an increase in non-apoptotic cell 
death known as autophagy (Qian et al., 2007).  Additionally, male Wistar rats exposed to 
2.5 and 5 mg/L sodium arsenite in their drinking water had an increase in apoptotic cells 






Exposure to arsenic in utero or during infancy can be significant periods in which 
problems occurring with development may lead to diseases later in life (Daskeishi et al., 
2006). Arsenic has been shown to cross the placental barrier, causing numerous problems 
for the fetus, like stillbirth, spontaneous abortion, miscarriage, low birth weight, poor 
muscle movement or various forms of cancer (Ahmad et al., 2001).   
In Japan, back in 1955, around 13,000 infants were exposed to arsenic 
contaminated powdered milk. The company used low grade disodium hydrogen 
phosphate containing sodium arsenate in the production process and out of the initial 
count of exposed infants, 130 of them died (Daskeishi et al., 2006). A year after their 
exposure the infants showed little dermal symptoms so doctors assumed the worst was 
over. About thirteen years after the incident, a group of public health and school nurses 
began to notice some health problems in the survivors, including dermatological 
problems like leukaderma, melanosis, and rashes, as well as neurological problems like 
epilepsy, retardation, cerebral palsy, and cardiovascular problems (Tsuchiya, 1977; 
Daskeishi et al., 2006).  
In utero arsenic exposure has been studied in various animal models, ranging 
from rodents to fish (Waalkes et al., 2004a) (Gonzalez et al., 2007) (Tilton and Tanguay, 
2008). Exposures of 20ppm or greater caused a significant decrease in reproductive 
fecundity in mice which were caused by changes in the placenta, in which a defective 





the blood flow an embryo receives causing pregnancy complications like stillbirth, 
spontaneous abortion or miscarriage (He et al., 2007).  
The incidence of cancer also increases with arsenic exposure during gestation. 
When pregnant mice (C3H) were exposed to 42.5ppm or 85ppm sodium arsenite through 
their drinking water during gestation days 8 to 18 and offspring were grown to two years 
of age before sacrifice. The male offspring had an increased incidence of hepatocellular 
carcinoma and adrenal tumors, while females had increases in lung carcinomas, ovarian 
tumors, and uterine and oviduct preneoplasia compared to controls (Waalkes et al., 
2004b).  In a previous study done in our laboratory, parent mummichogs (Fundulus 
heteroclitus) were exposed to 230 ppb arsenic for 10 days preceding spawning and their 
offspring were analyzed for physiological changes along with changes in differential 
gene expression. The offspring showed a 2.8 fold increase in the incidence of a curved or 
stunted tail. Muscle specific proteins, tropomyosin and myosin light chain 2 were induced 
by 3.1- and 4.2-fold, respectively (Gonzalez et al., 2007).  This curved tail phenomenon 
was also shown in zebrafish that were exposed to 2.0mM of sodium arsenite.  Hatched 
embryos also had altered heart development, and aberrant somite and neuromuscular 
patterning that correlated to altered cell proliferation and genomic DNA methylation (Li 
et al., 2009). With these occurrences of tail deformities and an increase in muscle specific 






  Arsenic exposure has been shown to effect muscle–related proteins and muscle 
function in smooth and cardiovascular muscles.  Epidemiological studies in Bangladesh 
and Taiwan, two areas with exposure to high concentrations of arsenic, observed an 
increase in the development of hypertension leading them to believe that arsenic was a 
possible cause (Chen et al., 1995; Rahman et al., 1998). Hypertension can develop from a 
condition known as atherosclerosis, in which there is an accumulation of lipoprotein in 
the arteries.  Arsenic has been shown to accelerate atherosclerosis in the offspring of 
ApoE-knockout mice, who were given drinking water that contained 85 mg/L, by 
reducing the arteries ability to relax (Srivastava et al., 2007).  Additionally, arsenic has 
been able to alter the arteriolar matrix in mice, exposed to 50 ppb sodium arsenite, by 
reducing collagen, elastin, and actin (Hays AM, 2008). During an in utero and postnatal 
exposure to 100 ppb sodium arsenite was able to increase the amount of smooth muscle 
actin in the lungs (Lantz et al., 2008).   
The functional contractile unit of muscle consists of myosin bound to actin.  
When adenosine triphosphate (ATP) binds to the myosin cross bridge (MCB) active site 
it causes myosin to dissociate from the actin filament (Geeves and Holmes, 1999). The 
MCB then orientates itself to a 90° angle from the actin during the hydrolysis of ATP to 
adenosine diphosphate (ADP) and inorganic phosphate. The products from hydrolysis are 
released and this causes the bound MCB to revert to its original angle of 45°, leading to a 
propelling action that moves the actin filament past the myosin filament (Geeves and 





Tropomyosin wraps itself around actin and hinders the attachment of the myosin cross 
bridge during low Ca+2 levels (Wolska and Wieczorek, 2003). As these levels rise, they 
activate tropomyosin which will in turn move to a non-blocking position to allow the 
myosin cross bridge to re-bind to actin during the contraction process.  
 
                           
When smooth muscle, in the form of intact aortic rings, were exposed to 10µM 
monomethylarsonous acid (MMAIII), there was an irreversible relaxation of the blood 
vessel (Bae et al., 2008).  This failure to compress the blood vessels increases the risk for 
various cardiovascular diseases through the alteration of tonal regulation and blood 
circulation (Gutstein and Pérez, 2004).  
Since arsenic has been shown to interact with various muscle types and our 
laboratory saw an increase in muscle-specific proteins after parental arsenic exposure to 
fish, we investigated the potential impacts of sodium arsenite during the differentiation 
C2C12 mouse skeletal muscle cells from myoblasts to myotubes (Fig. 5).     





            
 
 
Our hypothesis is that when the myoblast cells are incubated with arsenic, an 
inappropriate timing of transcription factor and muscle-specific protein expression may 
be in part responsible for some of the developmental abnormalities seen in our lab’s 
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Arsenic is a known human toxicant, that causes diseases such as skin lesions, 
pigmentation changes, increase of keratoses, cardiovascular diseases, lung, bladder, and 
skin cancer, and developmental problems (DeSesso et al., 1998) (Tondel M., 1999; 
Mandal and Suzuki, 2002; Shi et al., 2004; Soffritti et al., 2006; Hill et al., 2008). 
Exposure can be from natural sources like soil, water, or food sources and from human 
sources like industrial pollution, mining and medication, but the most common exposure 
is through drinking water (Mandal and Suzuki, 2002). The World Health Organization 
(WHO) has changed its standard for arsenic concentrations in water throughout the 
decades with the increasing concern for its adverse effects on human health (WHO, 
2003). Many of the epidemiologic studies are in areas of high arsenic concentrations 
which produce more consistent dose-response correlations.  More recently, studies have 
begun to focus on exposure to lower arsenic concentrations (Cantor and Lubin, 2007; 
Reichard et al., 2007) (Schoen et al., 2004). 
In utero and postnatal development are critical periods in which toxicants can 
disrupt gene expression and organ development which can result in problems later in life 
(Dolinoy et al., 2007) (Morley, 2006) (Wlodarczyk et al., 1998) (Wlodarczyk et al., 
2001).  Arsenic has been shown to cross the placental barrier, and studies in rodent 
models have shown that dams exposed to arsenic in their drinking water had an increase 





activity (Ahmad et al., 2001) (Waalkes et al., 2003; Waalkes et al., 2004a; Jin et al., 
2005; He et al., 2007).  Additionally, arsenic exposure in utero increases cancer 
incidence in the offspring (Diwan et al., 2000) (Waalkes et al., 2007) (Waalkes et al., 
2008) (Ahlborna et al., 2009).  
In utero arsenic exposure also alters muscle function and muscle-related protein 
expression in the offspring.  For example, mummichogs (Fundulus heteroclitus) that 
were parentally-exposed to arsenic had an up-regulation of tropomyosin and myosin light 
chain 2 (Gonzalez et al., 2006). Zebrafish exposed during embryogenesis showed altered 
heart development, and somite and neuromuscular patterning that correlated to altered 
cell proliferation and genomic DNA methylation (Li et al., 2009).  In utero exposure 
accelerated atherosclerosis in the offspring while reducing the ability of their smooth 
muscle to properly relax (Srivastava et al., 2007). An alteration to muscular regulatory 
factors during somitogensis in zebrafish has resulted in impaired development of fast 
skeletal muscle (Tilton and Tanguay, 2008).  Arsenic exposure in utero has resulted in 
changes in the vascular matrix by decreasing the amounts of collagen and elastin (Hays 
AM, 2008). In utero exposure can also lead to perturbation in placental vasculogenesis 
that can lead to spontaneous abortions (He et al., 2007). It has also found that in utero or 
early postnatal arsenic exposure can lead to an irreversible change in airway smooth 
muscle by altering the expression of several genes that regulates the extracellular matrix 
(Lantz et al., 2008).  Additionally, arsenic exposure to frogs prior to metamorphosis 





Muscle development is regulated by several transcription factors that differentiate 
stem cells into smooth muscle, cardiac muscle, or skeletal muscle.  In embryogenesis, 
progenitor cells originating in the somites develop into primary muscle fibers through a 
number of regulatory factors and the regulatory factor that initiates the conversion of a 
skeletal muscle myoblast to a myotube is myogenin (Buckingham et al., 2003). This 
protein is essential for proper skeletal muscle development while the loss of Myf5 and 
MyoD will have little effect in its formation due to other family members that can act as 
substitutes (Braun et al., 1992; Rudnicki et al., 1992; Hasty et al., 1993). The myogenin 
gene is activated by a histidine- and cysteine-rich region and helix III domains of MyoD 
but before that can take place the 5’-flanking region of the gene needs to be unmethylated 
(Sartorelli and Caretti, 2005) (Fuso et al., 2001). In growth media with C2C12 cells, the 
5’-flanking region of the myogenin gene will be completely methylated, which will result 
in a silent gene but in differentiation media (serum free) the region will be completely 
demethylated within 48 hours (Fuso et al., 2001).  When S-adenosylmethionine (SAM) is 
administered to C2C12 cells it can repress expression of myogenin by delaying the 
demethylation of the 5’-flanking region on the myogenin gene (Fuso et al., 2001) 
(Lucarelli et al., 2001). Once produced the myogenin protein is activated through 
phosphorylation by protein kinase C in its conserved DNA-binding domain (Li et al., 
1992). Demethylation of the myogenin promoter correlates with increased myogenin 
expression during muscle differentiation (Scarpa et al, 1996) (Lucarelli et al, 2001).  This 
is likely due to a disruption of the methyl CpG-binding protein 2 (MBD2) complex which 





Another function of methylation is to detoxify arsenic using SAM as a cofactor.  
Arsenic methyltransferase (As3MT) form tri- and pentavalent methylated species, such as 
methylarsonous acid [MAs(III)], methylarsonic acid [MAs(V)], dimethylarsinous acid 
[DMAs(III)], dimethylarsonic acid [DMAs(V)], trimethylarsine oxide [TMAs(V)O] and 
trimethylarsine [TMAs(III)] (Thomas et al., 2001) (Thomas et al., 2007). The use of 
SAM to detoxify arsenic likely depletes the same cofactor needed by DNA 
methyltransferase to methylate genes for silencing.  This can lead to altered gene 
methylation and aberrant gene expression (Reichard et al., 2007) (Poirier, 1994). 
The present study examined muscle cell differentiation using low concentrations 
of arsenic, and determined that arsenic does indeed alter muscle cell differentiation and 












Methods and Materials 
Cell Culture and Viability 
Mouse muscle C2C12 cells from ATCC (#CRL-1772, Manassas, VA) were maintained 
in DMEM supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% 
penicillin/streptomycin (growth media) at 37° C in a humidified incubator containing 5% 
CO2.   To differentiate the cells, the medium was replaced with DMEM supplemented 
with 2% horse serum, 1% L-glutamine and 1% penicillin/streptomycin (differentiation 
media) (Kubo, 1991). 
To determine the appropriate levels of arsenic exposure, C2C12 cells were seeded in 
quintuplet in a 96-well culture plate at a concentration of 2000 cells/well in growth 
media.  Cells were cultured in increasing concentrations of sodium arsenite for three days 
(n=5 wells per concentration) before viability was assessed spectrophotometrically using 
a MTS/phenazine methosulfate assay (Cory et al., 1991). From the assay, 20nM sodium 
arsenite was shown to be non-toxic, so this concentration was used for our experiments.  
Quantification of Multinucleated Myocytes 
To examine the rate of multinucleated myocyte formation, C2C12 cells were seeded at 
8.6x102 cells/ well in 6 well plates, and cultured with or without 20nm sodium arsenite as 
described above. The cells were examined on differentiation days 0, 1, 2, 3, and 4 (n=6 
per group per day).  To determine the number of myotubes formed, cells were fixed in 





giemsa stain in 100mM phosphate buffer for 20 minutes.  Cells were considered to be 
multinucleated if they contained 3 or more nuclei (Duan and Gallagher, 2009).  A 
multinucleation index was calculated by dividing the total number of cells by the number 
cells containing >3 nuclei.  The average multinucleation index was calculated for each 
group and day, and statistical differences were determined by Student’s t-test. 
Arsenic Exposure and Real-time PCR 
C2C12 cells were plated at 5000 cells/ 100mm dish (Corning, Corning, NY) in either 
growth medium or in growth medium containing 20nM sodium arsenite.   On the fourth 
day, cells were washed twice with PBS and either differentiation medium alone or 
differentiation medium containing 20nM sodium arsenite. Cells were harvested on days 
0, 1, 2, 3, and 4 (n=4 per group per day) by scraping into TriReagent (Sigma-Aldrich, St. 
Louis, MO) to extract total RNA.   RNA concentrations were determined by 
spectrophotometry.  2µg RNA was incubated with 0.4mM deoxynucleotide mix, 2ng 
random hexamers, and 1000U MMLV reverse transcriptase (Promega, Madison, WI) for 
1 hour at 37° C to prepare cDNA.  The expression of myogenin, myosin light chain 2, 
and tropomyosin was quantified by real-time PCR (IQ5, Bio-Rad, Hercules, CA).  Each 
reaction contained RT² SYBR® Green qPCR Master Mix (SABiosciences, Frederick, 
MD), 400nM primer, and 40ng cDNA, and was incubated at 95oC for 15 seconds 
followed by 60 seconds at the appropriate annealing temperature (Table 1).  Samples 
were run in triplicate and the entire experiment was repeated at least twice. The cycle 





known concentrations of the specific gene product.  GAPDH was used for normalization, 
the fold change was calculated by dividing the treated value by the control value and 
statistical differences were determined using Student’s t-test. 
Cellular Expression and Localization of Myogenin, Myosin Light Chain 2, and 
Tropomyosin 
C2C12 cells were seeded in Lab-tek II eight well coverglass slides (Nunc) at a 
concentration of 100 cells/well.  Cells were cultured with or without 20nM sodium 
arsenite as described above and examined for specific protein expression on 
differentiation days 0, 1, 2, 3, and 4 (n=8 per protein per group per day).  At the 
appropriate time point, the medium was removed and the cells were incubated in 
blocking buffer (1% bovine serum albumin, 0.1% Triton-X100 in 1X PBS) for 1 hour and 
washed.   Cells were then incubated with the appropriate primary antibody for 1 hour 
(myogenin: 1:100 dilution, Imgenex # IMG-131; myosin light chain 2: 1:50 dilution, 
Santa Cruz #C-17; tropomyosin: 1:50 dilution, Santa Cruz # F-6).  After washing, 
1 g/ml secondary antibody conjugated to Alexa Flour 488 (Invitrogen, Carlsbad, CA) 
was incubated with the cells for 1 hour and then the cells were incubated in 300mM 
DAPI (Invitrogen,) for 15 minutes.  Cells were examined by conventional and confocal 
immunofluorescence on a Ti Eclipse Inverted Microscope (Nikon, Melville, NY).  
Quantification of myogenin was done by dividing the total number of nuclei by the 
number of nuclei that were expressing myogenin. Quantification for myosin light chain 2, 





software and acquiring the pixel intensity for Alexa Fluor 488. The mean pixel intensities 
for the individual cells were compared between controls and treatment with four fields 
per sample. These quantifications were done for each group and day, and statistical 
differences were determined by Student’s t-test. 
 
Cellular Concentration of S-Adenosyl Methionine 
S-adenosyl methionine (SAM) concentrations were determined using the Bridge-It SAM 
Fluorescence Assay (Mediomics, St. Louis, MO). C2C12 cells were plated at 5000 
cells/100mm dish. Culturing techniques were same as those done for Real-time PCR 
analysis. The cells were examined on differentiation days 0, 1, 2, 3, and 4 (n=4 per set per 
day).  At the respective time points, cells were washed with PBS and all visible liquid 
was removed.   Cells were scraped into microfuge tubes, homogenized using a 26 gauge 
needle, and analyzed by fluorimetry using 485nm for excitation and 665nm for emission.   
The relative fluorescence values were normalized to the amount of protein.  Samples 
were normalized to the amount of protein (Bio-Rad’s DC protein assay) and the average 
was determined for each group and time point.  Statistical differences were determined 









Arsenic exposure and effects on C2C12 mouse muscle cells 
Initial cell viability assays demonstrated that the LC50 of sodium arsenite in 
C2C12 cells was 5µM (data not shown), so concentrations lower than this were tested to 
determine whether they caused a delay in the differentiation of the cells.  Cells were 
cultured in growth media for 3 days and then cultured in differentiation medium, either 
with or without 20nM sodium arsenite.  Photographs were taken on the first day the 
differentiation media was added, and again over the next four days. In the 20nM arsenic 
exposed C2C12 cells on day 0 and day 1 of differentiation, there were no visible 
differences to that of control cells and both sets appeared predominantly as myoblasts 
(Figure 1 A and D). There was a noticeable decrease in the amount of myotube formation 
on day two in the 20nM arsenic exposed cells compared to the controls (Fig.1 B and E). 
By day two control cells had withdrawn from the cell cycle process and were already 
fusing together to form myotubes. The arsenic exposed cells were only at beginning 
stages of differentiation, in which they were elongate in shape, but only contained one 
nuclei.  By day 3, the treated cells contained myotubes but not to the extent as the 
controls, yet by day 4 the arsenic exposed cells appeared the same as the controls (Fig.1C 
& F). C2C12 cells were also stained with giemsa during differentiation to determine the 
number of myotubes, which was considered to be those cells with 3 or more nuclei. There 
was a significant 17.4-fold increase in myotube formation in the controls on day two of 





was equivalent by days three and four (Fig. 1 graph). This is in agreement with what we 
visually in the C2C12 cell differentiation.  
Quantitative analysis of transcript levels from muscle transcription factor and 
muscle specific proteins 
 Gene expression was profiled using qPCR for myogenin, tropomyosin and 
myosin light chain 2.  Myogenin is the transcription factor that initiates the differentiation 
of a skeletal muscle myoblast to a myotube.  When C2C12 cells are cultured in growth 
medium, there was very low expression of myogenin in both unexposed and arsenic-
exposed cells.  However, by day 2 of differentiation, myogenin was significantly reduced 
by 1.4-fold in the arsenic-exposed cells (Figure 2A).  Myogenin mRNA expression was 
down-regulated in the arsenic-exposed cells on days 3 (2.4-fold) and 4 (3.2-fold) of 
differentiation.  The reduced expression of myogenin is likely causing the delay in 
differentiation in arsenic-exposed cells.   The levels of tropomyosin and myosin light 
chain 2 were also examined since they are integral proteins in muscle contraction.  
Tropomyosin expression in treated cells showed no difference when compared to control 
cells (Figure 2B).  Interestingly, the expression of myosin light chain 2 was up-regulated 
in the arsenic-exposed cells days 0, 3 and 4 by 2.6-, 2.2-, and 2.3-fold, respectively 
(Figure 2C).  






 Since changes were seen in transcript numbers for myogenin and myosin light 
chain 2 using real time PCR, the cells were investigated using immunofluorescence 
determine whether 20nM sodium arsenite would alter the expression and/or localization 
of myogenin, tropomyosin and myosin light chain 2.   Actin was also investigated since it 
has been shown to go through filament reorganization when exposed to arsenic in 
endothelial cells (Qian et al., 2004). Myogenin expression is restricted to the nuclei 
during myogenesis and in both controls (Figure 3 A-C) and treated cells (Figure 3 D-F). 
The number of nuclei expressing myogenin was significantly reduced in the arsenic-
exposed C2C12 cells by 1.6-fold on day two and 1.7-fold on three of differentiation 
(Figure 5A). However, on day four the number of nuclei expression myogenin in the 
arsenic-exposed cells is significantly increased by 1.3-fold (Figure 5A).  Tropomyosin 
appeared as filaments on day zero but this was replaced with an overall diffuse pattern of 
expression on the following days.  There were no differences in localization or mean 
expression intensities between the control and treated cells (Figure 4 G-L and Figure 5 
C).  Myosin light chain 2 and actin both appear as individual filaments throughout the 
treatment period with no signs of disorganization (Figure 4 A-F and M-R).  Likewise, 
there were no differences in mean intensities between treatment and control cells (Figure 
5 B and D). 
Quantification for S-adenosyl methionine 
  The cofactor S-adenosyl methionine (SAM) is normally used to methylate DNA 





transcription factor myogenin, Sam was investigated to see if there was also a reduction 
with arsenic exposure. It was investigated using Mediomics Bridge-It® S-Adenosyl 
Methionine (SAM) Assay; however, there were no differences in S-adenosyl methionine 


















These results illustrate that 20 nM sodium arsenite can alter myoblast 
differentiation by reducing the expression of the transcription factor myogenin. 
Additionally, arsenic can alter the gene expression of the muscle-specific protein myosin 
light chain 2 during the differentiation process.  To our knowledge, this is the first study 
that has examined the affects of sodium arsenite in the development of skeletal muscle 
cells while previous studies have looked at muscle development either in vivo or in vitro 
after arsenic exposure using  smooth muscle (He et al., 2007; Lantz et al., 2008).  When 
either 50ppb or 100ppb of arsenic were administered to female mice in their drinking 
water, their offspring had increases in the amount of smooth muscle mass and actin 
protein levels in the lung, especially in airways smaller than 100 µm in diameter (Lantz et 
al., 2008). This demonstrates that arsenic can interfere in the development of the vascular 
system. When pregnant mice ingested drinking water containing 20ppm or higher of 
sodium arsenite, there was a decrease in their fecundity and a defective formation of 
blood vessels in the placenta (He et al., 2007). This kind of dysfunction in vascular 
development was believed to contribute to spontaneous abortion seen in the study (He et 
al., 2007).   
In our study, a developmental delay was observed when the transcription factor 
myogenin was reduced in the arsenic-treated cells during days 2, 3 and 4.  This coincides 
with the differentiation delay recorded by photography.  We had hypothesized that the 
alterations in myogenin expression might be due to differences in methylation patterns in 





arsenic exposure, like a hypermethylation in the promoter region of the tumor suppressor 
gene p53 in human lung adenocarcinoma A549 cells or a hypermethylation of p53 that 
has occurred in rat liver epithelial cell line when exposed to arsenic (Mass and Wang, 
1997; Zhao et al., 1997).  This hypermethylation of the promoter region p53 and another 
tumor suppressor gene p16 has also been shown in blood samples obtained from people 
who have chronically exposed to arsenic (Chanda et al., 2006).  In one study, a decrease 
in SAM concentrations occurred during arsenic exposure of TRL 1215 rat liver cells 
(Zhao et al., 1997). Human HaCaT keratinocytes exposed to 25µM arsenite also saw a 
decrease in SAM concentrations (Reichard et al., 2007). Since SAM is used by both 
arsenic methyltransferase and DNA methyltransferase, a competition may occur causing 
a reduction in SAM levels to the point that the replenishment of SAM cannot keep up 
with the demand.  It has even been shown that arsenic toxicity can be rescued by the 
administration of 170nM of SAM (Ramírez et al., 2007). In HeLa cells that were exposed 
to 10µM sodium arsenite which can cause aneuploidy to occur, the addition of 170nM of 
SAM reduced the frequency of this chromosome abnormality (Ramirez et al., 2003).  As 
for our experiment, we found no changes in SAM levels between control and arsenic-
exposed C2C12 cells.  This might be due to the type of cell used, as some cells have are 
considered to be low methylators, such as urothelial cells and fibroblasts (Dopp et al., 
2009).   If C2C12 cells are highly active in the methylation of arsenic, this might account 
for the SAM concentrations from C2C12 cells in the present study being extremely low, 





pools, studies are underway to investigate methylation patterns of the myogenin 
promoter.    
As for the examination of muscle specific proteins, 20 nM sodium arsenite was 
also able to alter the mRNA levels of the muscle-specific protein myosin light chain 2, 
resulting in an average increase of 2.1 fold over controls. This is consistent with previous 
results in a model fish species termed mummichogs, in which the investigators also saw 
an increase in myosin light chain 2 (Gonzalez et al., 2007).   An increase in the amount of 
myosin light chain proteins could cause a dysfunction to the muscle’s contractile force 
(Schiaffino and Reggiani, 1996). When myosin light chain 2 units were removed from 
myosin heavy chain, there was a reduction in the filament velocity (Lowey et al., 1993). 
So an increase in myosin light chain 2 units might cause an over contraction by 
increasing the filament velocity.   However, using immunofluorescence, there was no 
difference in myosin light chain 2, tropomyosin, or actin protein expression or 
localization in arsenic-exposed cells.  In endothelial cells, an exposure of 10µM arsenic 
was needed to see a change in the organization of actin filaments (Qian et al., 2004). This 
amount is 500 times higher than the concentration we used, which may be why we can 
detect differences in some of the transcript levels but not in protein expression.  
 This study shows that 20 nM of sodium arsenite was able to interfere with the 
differentiation of myoblasts to myotubes by reducing the production and expression of 
myogenin.  This could translate into a loss of muscle mass or disorganization of muscle 








Figure 1. C2C12 cells differentiation from myoblast to myotube.  
Both control (A-C) and exposed samples (D-F) had myoblast at day 0 after three days of 
growth media and zero days of differentiation media. Myotube formation is indicated by 
the white arrows and elongation is indicated by asterisks.   Photographs are representative 
examples from  4 plates/day/group.  Myotubes of 3 or more nuclei were counted for 
comparison (G) between controls (black bars) and treatment (white bars).   Myotubes 
were counted from 4 random areas per plate (n=4 plates/time/group)and statistical 








Figure 2. Real-time PCR for myogenin, myosin light chain 2 and tropomyosin 
Alteration of myogenin (A), tropomyosin (B) and myosin light chain 2 (C) expression 
was determined by real-time PCR. Values were normalized against GAPDH as a 
housekeeping gene, with each sample run in triplicate (n=4 plates/day/group).  Statistical 
differences were determined by Student’s t-test (p < 0.05). Control samples are the black 









Figure 3. Localization and expression of myogenin through immunofluorescence 
Immunofluorescence was used to examine myogenin localization and cells were 
counterstained with DAPI.  Rows A, B, C are control cells for day 0, 2, and 4, 
respectively. Rows D, E, F are treated cells for day 0, 2, and 4. White arrows indicate 








Figure 4. Immunofluorescence of myosin light chain 2, tropomyosin and actin 
Immunofluorescence of muscle specific-proteins:  myosin light chain 2 (rows A-F) - control cells 
in rows A-C and treated cells rows D-F; tropomyosin (rows G-L) - control cells in rows G-I and 
treated cells in rows J-L; actin (rows M-R) - control cells in rows M-O and treated cells in rows 
P-R.  In each set the first row is day 0, second row is day 2 and third row is day 4. Pictures are 














Figure 5. Percentage of expression for 
myogenin and expression intensities of 
myosin light chain 2, tropomyosin and 
actin 
The percentage of nuclei expressing 
myogenin (A) was determined by comparing 
control cells (black bars) to treated cells 
(white bars), which was determined by 
counting the number of nuclei expressing 
myogenin per total cells in each photo taken 
(n ≥ 5). For the mean intensities of myosin 
light chain 2 (B), tropomyosin (C) and actin 
(D) control cells (black bars) were compared 
to treated cells (white bars) cultures (n=4). 
NIS-elements software was used to outline 
individual cells to acquire their intensities 
and statistical differences were determined 













Figure 6. S-adenosyl methionine quantification  
SAM levels were unaffected by the addition of 20nm sodium arsenite (white bars) compared to 
control values (black bars). Samples were done in triplicate on a 96-well plate and statistical 


















To reiterate the goal of this study, we wanted to see how a submicromolar 
concentration of sodium arsenite would affect the differentiation process of C2C12 
mouse myoblast. What was observed was a delay in differentiation that began on day 2 
after change from growth media to differentiation media. This was correlated to a 
decrease in myotube formation in the treated cells and a decrease in myogenin gene 
expression.  This study provides evidence that 20nM sodium arsenite might have the 
ability to act as developmental toxicant.  
Future studies examining the mechanism of myogenin reduction could investigate 
the methylation pattern of the myogenin promoter region. It has been shown that arsenic 
can cause a hypermethylation in the promoter regions of the tumor suppressor gene p53 
and oncogene K-ras during low microcmolar concentration exposure which regulate cell 
cycle processes (Mass and Wang, 1997; Benbrahim-Tallaa et al., 2005). A 
hypermethylation in the promoter region of myogenin could cause the repression that was 
seen in this experiment.  
In addition, investigation of the genes that regulate the cell cycle, like proto-
oncogenes and oncogenes, might be considered because an alteration could prevent a cell 
from exiting mitosis to begin differentiation. Some genes of interest could be cyclin-
dependent kinase (cdk) inhibitor p21, c-myc or E2F-1, along with cdk2, cdk4, and cdk6. 
The cdk inhibitor p21 causes an irreversible cell cycle arrest with its induction in C2C12 





and Perlman, 1997). If the cdk inhibitor p21 were to be down regulated with arsenic 
exposure while cdk2, cdk4, and cdk6 were up-regulated, this could delay the C2C12 
cells’ progression to differentiation. As for c-myc, an increase in its expression has been 
show to inhibit a cell from exiting the cell cycle in epithelia and murine fibroblast 
(Freytag and Geddes, 1992). During the differentiation of murine preadipocyte fibroblasts 
into adipocytes in vitro, the cells were inhibited during short term exposure to 
concentrations ≥3µM sodium arsenite (Trouba et al., 2000b). This concentration was able 
to keep the cells in a mitogenic stage even in conditions that should have induced 
differentiation.  In  a separate study published by this group, these fibroblasts had 
increased c-myc and E2F-1 levels after arsenic exposure, which may explain the 
inhibition of differentiation (Trouba et al., 2000a).  
The examination of the methylation pattern on the myogenin promoter region, 
possibly using a ChIP-on-chip assay, would determine if myogenin is being directly 
repressed by arsenic due to an altered methylation pattern.  Determination of the 
transcript levels and protein expression for cdk inhibitor p21, c-myc, E2F-1, along with 
cdk2, cdk4, and cdk6 would be able to tell if the delay seen in the C2C12 cell 
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